Teva net up; Copaxone, respiratory strong

$103 million. The increase stems particularly from higher sales of the Plan B contraceptive. Sales of Azilect for Parkinson's disease rose 39% to $64 million. At Oct. 23, Teva had 210 product applications awaiting final clearance by the U.S. Food and...